Infectious disease
With the U.S. Food and Drug Administration’s vaccines advisory committee meeting being held today to discuss the Johnson & Johnson vaccine and blood clotting, there’s even more interest in what’s going on in the pandemic than usual. Here’s a look at some of the top stories.
It was a busy week for non-COVID-19-related clinical trial news, while fairly quiet on the COVID-19 arena. Here’s a look.
Molecular Partners announced yesterday it has filed for a $100 million initial public offering with the Securities and Exchange Commission in the U.S., funding which will go toward supporting the company’s work in the development of protein-based treatments for COVID-19 and various cancers.
A new study suggests that many patients with long-term COVID-19 symptoms still experience health issues six months following infection, are survivors with “long haul” disease have a greater risk of dying and use a more significant number of medications than patients who have fully recovered from the virus.
Ocugen’s plan to bring a COVID-19 vaccine developed by India-based Bharat Biotech later this year remains on track following an interim analysis of Phase III data that shows the vaccine demonstrated a 78% efficacy against mild to moderate infection and 100% efficacy against severe COVID-19.
At the end of February, the U.S. was averaging 65,686 new COVID-19 cases per day. Fast-forward two months and that number is nearly identical at 64,814.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Novavax is plugging along to get their COVID-19 vaccine candidate, NVX-CoV2373, through late-stage clinical trials and authorized in the U.S. and elsewhere.
The U.S. FDA has requested that Emergent BioSolutions temporarily pause production of ingredients for the Johnson & Johnson COVID-19 vaccine at their facility in Baltimore.
ApiJect’s syringe is designed to be prefilled with a dose of a vaccine before it is shipped out to be used by doctors, pharmacists, hospitals, and many of the vaccination centers set up across the country. NBC noted that the prefilled technology had not been approved in the U.S.
PRESS RELEASES